xRead Articles - October 2022

(NIH) under Award Number 5T32DC000022 and by the National Center for Advancing Translational Sciences of the NIH under Award Number UL1TR002345. The con tent is solely the responsibility of the authors and does not necessarily represent the of fi cial views of the NIH. REFERENCES 1. Song WJ, Chang YS, Faruqi S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J 2015;45:1479 – 1481. 2. Bastian ZJ, Bastian RW. The use of neuralgia medications to treat sensory neuropathic cough: our experience in a retrospective cohort of thirty-two patients. PeerJ 2015;3:2015. 3. Altman KW, Noordzij JP, Rosen CA, Cohen S, Sulica L. Neurogenic cough. Laryngoscope 2015;125:1675 – 1681. 4. Hoppo T, Komatsu Y, Jobe BA. Antire fl ux surgery in patients with chronic cough and abnormal proximal exposure as measured by hypopharyngeal multichannel intraluminal impedance. JAMA Surg 2013;148:608 – 605. 5. Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS. Treatment of unexplained chronic cough: CHEST guideline and expert panel report. Chest 2016;149:27 – 44. 6. Lewis SZ, Diekemper R, Ornelas J, Casey KR. Methodologies for the devel opment of CHEST guidelines and expert panel reports. Chest 2014;146: 182 – 192. 7. Ryan NM, Gibson PG. Gabapentin for idiopathic chronic cough: a random ised controlled trial. Lung 2012;190:64. 8. DePietro JD, Stein DJ, Calloway N, Cohen SM, Noordzij PJ. U.S. practice variations in the treatment of chronic laryngopharyngeal neuropathy. Laryngoscope 2014;124:955 – 960. 9. Ryan NM, Vertigan AE, Birring SS. An update and systematic review on drug therapies for the treatment of refractory chronic cough. Expert Opin Pharmacother 2018;19:687 – 711. 10. Chamberlain S, Birring SS, Garrod R. Nonpharmacological interventions for refractory chronic cough patients: systematic review. Lung 2014;192: 75 – 85. 11. Dhillon VK. Superior laryngeal nerve block for neurogenic cough: a case series. Laryngoscope Investig Otolaryngol 2019;4:410 – 413. 12. Sasieta HC, Iyer VN, Orbelo DM, et al. Bilateral thyroarytenoid botulinum toxin type a injection for the treatment of refractory chronic cough. JAMA Otolaryngol Head Neck Surg 2016;142:881 – 888. 13. Litts JK, Fink DS, Clary MS. The effect of vocal fold augmentation on cough symptoms in the presence of glottic insuf fi ciency. Laryngoscope 2018;128: 1316 – 1319. 14. Higgins JPT, Thomas J, Chandler J, et al. In: Cochrane. Cochrane Hand book for Systematic Reviews of Interventions . Version 6.0; 2019. www. training.cochrane.org/handbook. Accessed June 30, 2020. 15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177 – 188. 16. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629 – 634. 17. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodo logical index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003;73:712 – 716. 18. Sterne JAC, Savovi c J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. 19. Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet Respir Med 2015;385:1198 – 1205. 20. Afferent Pharmaceuticals Inc. Effect of Gefapixant (AF-219/MK-7264) on Cough Re fl ex Sensitivity; 2015. https://clinicaltrials.gov/ct2/show/ NCT02397460. Accessed April 12, 2020. 21. Bastian RW, Vaidya AM, Delsupehe KG. Sensory neuropathic cough: a com mon and treatable cause of chronic cough. Otolaryngol Head Neck Surg 2006;135:17 – 21. 22. Belvisi MG, Birrell MA, Wortley MA, et al. XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough. Am J Respir Crit Care Med 2017;196: 1255 – 1263. 23. Birring SS, Wijsenbeek MS, Agrawal S, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fi brosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med 2017;5:806 – 815. 24. Bowen AJ, Nowacki AS, Contrera K, et al. Short- and long-term effects of neuromodulators for unexplained chronic cough. Otolaryngol Head Neck Surg 2018;159:508 – 515. 25. Chamberlain Mitchell SA, Garrod R, Clark L, et al. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax 2017;72: 129 – 136. 26. Chaudhuri R, McMahon AD, Thomson LJ, et al. Effect of inhaled corticoste roids on symptom severity and sputum mediator levels in chronic persis tent cough. J Allergy Clin Immunol 2004;113:1063 – 1070. 27. Merck Sharp & Dohme Corp. Study of Gefapixant (MK-7264) in Adult Japa nese Participants With Unexplained or Refractory Chronic Cough (MK

7264-033);

2019.

https://clinicaltrials.gov/ct2/show/NCT03482713.

Accessed April 12, 2020. 28. Dickinson RS, Morjaria JB, Wright CE, Morice AH. Is opiate action in cough due to sedation? Therapeutic Adv Chronic Dis 2014;5:200 – 205. 29. Dion GR, Teng SE, Achlatis E, Fang Y, Amin MR. Treatment of neurogenic cough with tramadol: a pilot study. Otolaryngol Head Neck Surg 2017; 157:77 – 79. 30. Dong R, Xu X, Yu L, et al. Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal re fl ux induced chronic cough. Aliment Pharm Ther 2019;49:714 – 722. 31. Halum SL, Sycamore DL, McRae BR. A new treatment option for laryngeal sensory neuropathy. Laryngoscope 2009;119:1844 – 1847. 32. Hodgson D, Anderson J, Reynolds C, et al. The effects of azithromycin in treatment-resistant cough: a randomized, double-blind, placebo-controlled trial. Chest 2016;149:1052 – 1060. 33. Hong JY, Kim JH, Park S, Hwang YI, Jung KS, Jang SH. Ef fi cacy and pre dictors of response to inhaled corticosteroid treatment for chronic cough. Korean J Intern Med 2019;34:559 – 568. 34. Menlos Therapeutics Inc. Study of the Ef fi cacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough; 2018. https:// clinicaltrials.gov/ct2/show/NCT03282591. Accessed April 12, 2020. 35. Jang M, Rubin SJ, Stein DJ, Noordzij JP. Randomized double blind trial of amitriptyline versus placebo in treatment of chronic laryngopharyngeal neuropathy. Am J Otolaryngol 2017;38:683 – 687. 36. Jeyakumar A, Brickman TM, Haben M. Effectiveness of amitriptyline ver sus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. Laryngoscope 2006;116:2108 – 2112. 37. Kapela SL, Vertigan AE, Gibson PG. Speech pathology intervention for chronic refractory cough: a pilot study examining the bene fi t of using pre recorded videos as an adjunct to therapy. J Voice 2019;10:10. 38. Lee B, Woo P. Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment. Ann Otol Rhinol Laryngol 2005;114:253 – 257. 39. Morice AH, Kitt MM, Ford AP, et al. The effect of gefapixant, a P2X3 antag onist, on cough re fl ex sensitivity: a randomised placebo-controlled study. Eur Respir J 2019;54:1900439. 40. Morice AH, Menon MS, Mulrennan SA, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med 2007;175:312 – 315. 41. Norris BK, Schweinfurth JM. Management of recurrent laryngeal sensory neuropathic symptoms. Ann Otol Rhinol Laryngol 2010;119:188 – 191. 42. Pizzichini MMM, Pizzichini E, Parameswaran K, et al. Nonasthmatic chronic cough: no effect of treatment with an inhaled corticosteroid in patients without sputum eosinophilia. Can Respir J 1999;6:323 – 330. 43. Qiu Z, Wei W, Yu L, et al. Ef fi cacy and safety of modi fi ed sequential three step empirical therapy for chronic cough. Respirology 2010;15:830 – 836. 44. Ribeiro M, Pereira CADC, Nery LE, Beppu OS, Silva COS. High-dose inhaled beclomethasone treatment in patients with chronic cough: a randomized placebo-controlled study. Ann Allergy Asthma Immunol 2007;99:61 – 68. 45. Sadeghi MH, Wright CE, Hart S, Crooks M, Morice A. Phenotyping patients with chronic cough: evaluating the ability to predict the response to anti in fl ammatory therapy. Ann Allergy Asthma Immunol 2018;120:285 – 291. 46. Simpson CB, Tibbetts KM, Loochtan MJ, Dominguez LM. Treatment of chronic neurogenic cough with in-of fi ce superior laryngeal nerve block. Laryngoscope 2018;128:1898 – 1903. 47. Smith J, Allman D, Badri H, et al. The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1). Chest 2020;157: 111 – 118. 48. Smith JA, Kitt MM, Morice AH, et al. Gefapixant, a P2X3 receptor antago nist, for the treatment of refractory or unexplained chronic cough: a ran domised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med 2020;8:775 – 785. 49. Stein DJ, Noordzij PJ. Amitriptyline for symptomatic treatment of idio pathic chronic laryngeal irritability. Ann Otol Rhinol Laryngol 2013;122: 20 – 24. 50. Ternesten-Hasseus E, Johansson EL, Millqvist E. Cough reduction using capsaicin. Respir Med 2014;109:27 – 37. 51. Vertigan AE, Kapela SL, Ryan NM, Birring SS, McElduff P, Gibson PG. Pregabalin and speech pathology combination therapy for refractory chronic cough a randomized controlled trial. Chest 2016;149:639 – 648. 52. Vertigan AE, Kapela SM, Franke I, Gibson PG. The effect of a vocal loading test on cough and phonation in patients with chronic cough. J Voice 2017; 31:763 – 772. 53. Vertigan AE, Theodoros DG, Winkworth AL, Gibson PG. A comparison of two approaches to the treatment of chronic cough: perceptual, acoustic, and electroglottographic outcomes. J Voice 2008;22:581 – 589. 54. Xu XH, Yang ZM, Chen Q, et al. Therapeutic ef fi cacy of baclofen in refrac tory gastroesophageal re fl ux-induced chronic cough. World J Gastroenterol 2013;19:4386 – 4392. 55. Yang J, Crawley B, Dehom S, Krishna P, Murry T. Chronic refractory cough: objective improvement with aerodynamic-focused. J Voice 2019; S0892-1997(19)30200-0. 56. Young EC, Brammer C, Owen E, et al. The effect of mindfulness meditation on cough re fl ex sensitivity. Thorax 2009;64:993 – 998. 57. Yousaf N, Matos S, Birring SS, Pavord ID. Long-term low dose erythromy cin for unexplained chronic cough: a double-blind, randomised, placebo controlled trial. Thorax 2009;64:A16 – A17. 58. Zalvan C, Berzofsky C, Tiwari R, Geliebter J. Trigger reduction prior to sys temic drugs for neurogenic chronic cough. Laryngoscope 2019;129: 198 – 202.

Laryngoscope 132: January 2022

Wamkpah et al.: Multimodal Treatments for Neurogenic Cough

122

Made with FlippingBook - Online Brochure Maker